SCHEMBL7438348

SCHEMBL7438348

CN(C(=N)Nc1cccc(S(C)(=O)=O)c1)c1cc(Br)ccc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.46
SIGMAR1 Q99720 2/20 0.41
CA1 P00915 7/20 0.41
CA2 P00918 7/20 0.41
CA4 P22748 1/20 0.41
ALDH1A1 P00352 4/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 2/20 0.40
HSP90AA1 P07900 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CA12 O43570 5/20 0.39
CA9 Q16790 5/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CSNK2A1 P68400 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6720790 0.80 SIRT2 (0.43) SIRT2CA1CA2CA4ALDH1A1
SCHEMBL6720673 0.79 SIGMAR1 (0.63) SIGMAR1ALDH1A1KMT2AMAPTMAPK1
SCHEMBL6720743 0.79 SIGMAR1 (0.48) SIRT2SIGMAR1CA1CA2ALDH1A1
SCHEMBL6724320 0.79 RAB9A (0.46) SIGMAR1ALDH1A1KMT2AMEN1MAPT
SCHEMBL8334507 0.78 MEN1 (0.50) SIRT2CA1CA2ALDH1A1KMT2A
SCHEMBL6724367 0.78 MEN1 (0.49) SIGMAR1ALDH1A1KMT2AMEN1MAPT
SCHEMBL6720936 0.77 SIRT2 (0.39) SIRT2SIGMAR1CA1CA2CA4
SCHEMBL7445999 0.77 SIGMAR1 (0.41) SIGMAR1ALDH1A1KMT2AMEN1MAPT
Hydrochloric Acid SCHEMBL7208229 0.76 SIGMAR1 (0.40) SIRT2SIGMAR1CA1CA2CA4
SCHEMBL6716829 0.75 ALDH1A1 (0.45) SIGMAR1ALDH1A1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6156741-A Therapeutic substituted guanidines CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-12-05 US claimed
US-6153604-A Therapeutic substituted guanidines CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-11-28 US claimed
US-6147063-A NEUROTOXICITY CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-11-14 US claimed
EP-0705100-A4 THERAPEUTIC SUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE INC (US) 1996-05-29 EP claimed
EP-0705100-A1 THERAPEUTIC SUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE, INC. (US) 1996-04-10 EP claimed
WO-1994027591-A1 THERAPEUTIC SUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE, INC. (US) 1994-12-08 WO claimed
US-6156741-A Therapeutic substituted guanidines CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-12-05 US disclosed
US-6153604-A Therapeutic substituted guanidines CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-11-28 US disclosed
US-6147063-A NEUROTOXICITY CAMBRIDGE NEUROSCIENCE, INC. (US) 2000-11-14 US disclosed
CN-1126434-A Therapeutic substituted guanidines CAMBRIDGE NEUROSCIENCE INC (US) 1996-07-10 CN disclosed
EP-0705100-A4 THERAPEUTIC SUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE INC (US) 1996-05-29 EP disclosed
EP-0705100-A1 THERAPEUTIC SUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE, INC. (US) 1996-04-10 EP disclosed
WO-1994027591-A1 THERAPEUTIC SUBSTITUTED GUANIDINES CAMBRIDGE NEUROSCIENCE, INC. (US) 1994-12-08 WO disclosed